Clinical Trial Update: Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating whether tadalafil, a phosphodiesterase-5 inhibitor, affects systemic right ventricular size and function in patients with congen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Defect
• Transposition of the Great Arteries with Ventricular Inversion

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Heart Defects, Congenital, Transposition of Great Vessels With Ventricular Inversion | Phase 3 | Status: COMPLETED